Nexalin Technology Reports FDA Feedback And Reached Consensus On Nexalin's Design For Planned Anxiety And Insomnia Clinical Studies Of Its Gen-3 HALO Clarity Headset Device
Portfolio Pulse from Benzinga Newsdesk
Nexalin Technology has received feedback from the FDA and reached a consensus on the design for its planned clinical studies of the Gen-3 HALO Clarity Headset Device, which targets anxiety and insomnia.
June 03, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nexalin Technology has received FDA feedback and reached a consensus on the design for its planned clinical studies of the Gen-3 HALO Clarity Headset Device, which targets anxiety and insomnia.
The FDA feedback and consensus on the clinical study design are positive developments for Nexalin Technology, as they indicate progress towards potential market approval and commercialization of the Gen-3 HALO Clarity Headset Device. This could lead to increased investor confidence and a potential short-term boost in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100